drugset / Trial / NCT00967512
Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to Frontline Induction Course
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to assess whether treatment with cenersen in combination with 4 cycles of high and low-dose chemotherapy (idarubicin and cytarabine) improves the complete response rate in acute myelogenous leukemia (AML) patients ≥ 55 years of age who did not show a response (CR, CRi, or PR) to a single aggressive frontline induction course.
Timeline
- Start
- 2012-01
- Primary completion
- 2012-01
- Completion
- 2012-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | cenersen | Antisense oligonucleotide | 0.1 mg/kg | Intravenous |
| Background | Cytarabine | Small molecule | — | — |
| Background | Idarubicin | Small molecule | — | — |